What Is PMDD (Premenstrual Dysphoric Disorder)? Meaning, Symptoms, and How It Differs From PMS
A plain-English definition of PMDD (premenstrual dysphoric disorder): what it means, why it is a cyclical mood disorder driven by brain sensitivity to normal hormone shifts, and how it differs from PMS and PME.
Short Answer
Premenstrual dysphoric disorder (PMDD) is not just "bad PMS." It is a cyclical mood disorder: severe mood, body, sleep, appetite, and energy symptoms reliably switch on during the luteal phase — the one-to-two weeks after ovulation and before bleeding — and usually ease within a few days after the period starts. The difference is intensity and impairment: with PMDD, irritability, depression, anxiety, mood swings, brain fog, fatigue, cravings, insomnia, bloating, headaches, or breast tenderness can become strong enough to disrupt work, relationships, parenting, school, and the basic feeling of being yourself. (Johns Hopkins Medicine)
In the DSM-5, PMDD is listed under depressive disorders, and diagnosis depends on the pattern: at least five symptoms, at least one mood-related symptom, meaningful distress or impairment, and confirmation with prospective daily symptom ratings across at least two symptomatic menstrual cycles. That is why a blood test cannot "prove" PMDD. Your hormones may look normal on a lab report, while your nervous system is still reacting abnormally to the normal monthly rise and fall of ovarian hormones. (StatPearls / NCBI Bookshelf)
The best-supported biology is not "too much hormone" or "too little hormone." It is altered brain sensitivity to hormone change — especially to allopregnanolone (ALLO), a progesterone metabolite that normally modulates the GABA-A system, one of the brain's main calming and mood-regulating systems. In PMDD, the ALLO-GABA response appears dysregulated, so the same luteal-phase hormone shift that another person barely notices can feel like an abrupt change in threat sensitivity, stress tolerance, sleep, appetite, and emotional control. (*Neurobiology of Stress*, 2020)
PMDD is commonly estimated to affect about 3–8% of menstruating people, though estimates vary by study and diagnostic method. It is real, diagnosable, and treatable — and the first practical step is often simple but powerful: track symptoms daily across cycles so the timing becomes visible to you and to a clinician. (*Psychopharmacology*, 2016)
PMDD at a glance
PMDD is a cyclical mood disorder tied to the menstrual cycle, not "just bad PMS." In the DSM-5 framework, it sits under depressive disorders, but its pattern is what makes it distinct: symptoms rise predictably before menstruation, then ease after bleeding starts, with a clearer, lighter stretch afterward. DSM-5 wording is specific: in most cycles, symptoms are present in the final week before the onset of menses, begin to improve within a few days after menses starts, and become minimal or absent in the postmenstrual week. In real life, many patient-facing clinical resources describe the vulnerable window as the week or two before a period. (DSM-5 / NCBI Bookshelf)
The core of PMDD is mood and nervous-system reactivity: marked irritability or anger, mood swings, depressed mood or hopelessness, anxiety or feeling on edge. Around that, the body often adds fatigue, low energy, trouble concentrating, sleep changes, appetite changes or cravings, feeling overwhelmed, breast tenderness, bloating, headaches, or joint and muscle pain. The "why" is not that your ovaries are making abnormal hormone levels; the better-supported model is that the brain and stress-response systems are unusually sensitive to normal cyclical shifts, especially progesterone's neurosteroid metabolite allopregnanolone, which modulates GABA-A signaling. (DSM-5 / NCBI Bookshelf)
Estimated prevalence is commonly cited at about 3–8% of people in fertile/reproductive ages, though estimates vary depending on whether symptoms are confirmed prospectively. Diagnosis is pattern-based: a clinician looks for at least five symptoms, including at least one core mood symptom, causing meaningful distress or impairment, and confirms the timing with prospective daily symptom tracking for at least two menstrual cycles. There isn't a blood test or single objective lab marker that confirms PMDD; tracking matters because it helps separate PMDD from PMS, from PME — premenstrual worsening of an existing condition that is still present across the cycle — and from mood changes linked to perimenopause or other health issues. (*Psychopharmacology*, 2016)
PMDD vs PMS vs PME: the quick distinction
The difference is not "real vs not real." All three can feel real in your body. The useful question is what your symptoms are doing across the whole cycle: do they appear mainly before your period, do they become severe enough to take over your life, or are they part of an existing condition that gets louder premenstrually?
| | PMS | PMDD | PME (premenstrual exacerbation) |
|---|---|---|---|
| What it is | PMS is a pattern of physical and emotional symptoms before your period — things like bloating, breast tenderness, headaches, irritability, sadness, or mood swings. For many people it is mild; for some, it can still disrupt daily life. (Office on Women's Health) | PMDD is the severe, diagnosable end of the premenstrual-symptom spectrum. In DSM-5 language, it requires a cyclical pattern with five or more symptoms, including at least one core mood symptom, and clinically significant distress or impairment. (DSM-5 / NCBI Bookshelf) | PME means you already have another condition — such as depression, anxiety, bipolar disorder, migraine, or another medical/psychiatric condition — and that condition worsens before or around your period. It is not the same pattern as PMDD because the underlying symptoms do not fully disappear between cycles. (Clinical Psychology: Science and Practice / PMC) |
| Timing | PMS usually shows up after ovulation, in the luteal phase, and tends to ease once bleeding starts or within the first few days of the period. (Office on Women's Health) | PMDD symptoms typically rise in the final week before bleeding, start improving within a few days after bleeding begins, and are minimal or absent in the week after the period. (DSM-5 / NCBI Bookshelf) | PME can look "period-linked" because symptoms spike in the late luteal or perimenstrual window, but the condition is present outside that window too. The premenstrual phase turns the volume up; it does not create the whole problem from zero. (Clinical Psychology: Science and Practice / PMC) |
| Symptom-free window | PMS may be uncomfortable, but there is usually a lighter part of the cycle. In stricter clinical descriptions of premenstrual disorders, a symptom-free interval before ovulation helps separate cyclical symptoms from ongoing illness. (Premenstrual disorders review / PMC) | PMDD has a clearer "off switch": after menses, symptoms should drop back to minimal or absent for a stretch of the cycle. That symptom-free window is one reason daily tracking matters. (DSM-5 / NCBI Bookshelf) | PME usually has no true symptom-free window. You may feel worse before your period, but some baseline depression, anxiety, pain, fatigue, or other symptoms are still there during the rest of the month. (Clinical Psychology: Science and Practice / PMC) |
| Impairment | PMS can be annoying, draining, and physically uncomfortable, but it is often manageable with self-care, lifestyle changes, and symptom relief. If it regularly disrupts work, school, relationships, or basic routines, it deserves medical attention. (Cleveland Clinic) | PMDD interferes with functioning — work, relationships, parenting, school, decision-making, or feeling safe inside your own mind. It is not "bad PMS"; it is a severe cyclical mood disorder that can need targeted treatment. (Johns Hopkins Medicine) | PME impairment depends on the underlying condition and how sharply it worsens around the period. The treatment target may be different too: instead of treating PMDD alone, clinicians often need to treat the baseline condition and the menstrual-cycle trigger together. (Premenstrual exacerbation review / PMC) |
A practical rule: PMDD is about a cyclical on/off pattern; PME is about a chronic condition with a monthly surge. If you are unsure which one fits, track symptoms every day for at least two cycles — not just on the worst days. That pattern is often more useful than memory, because when you are in the luteal crash, your brain can make the whole month feel like it has always been that bad. (*BMC Women's Health* / PMC)
What PMDD is (and what it isn't)
Premenstrual dysphoric disorder is best understood as your cycle acting as a trigger, not as the root cause of a mood disorder. In PMDD, the monthly rise and fall of reproductive hormones seems to hit a nervous system that is unusually sensitive to those normal shifts. Research describes it directly: "Premenstrual Dysphoric Disorder (PMDD) is a cyclical condition similar to premenstrual syndrome (PMS), with symptoms arising in the late luteal phase" (*Journal of Health Psychology*, 2026) — but where PMS is disruptive, PMDD is disabling. It can affect work, relationships, sleep, parenting, and your ability to feel like yourself. That level of impairment is why DSM-5 recognizes PMDD in the depressive disorders section, rather than treating it as "bad PMS" or a personality problem.
What defines PMDD is the pattern. The symptoms are time-locked to the menstrual cycle: they usually build in the days before your period, during the luteal phase, and then improve after bleeding starts. Research characterizes it as "an emotional disorder characterized by symptoms of irritability, depression, anxiety, and sleep disturbances during the luteal phase of the menstrual cycle" (*Depression and Anxiety*, 2026). That predictable rise-and-fall — feeling like a different person for one to two weeks, then coming back toward baseline once the period begins — is the clue that separates PMDD from an ongoing depression or anxiety disorder. Clinically, PMDD symptoms are expected to ease within a few days after menses starts, with a clearer, lower-symptom interval in the follicular phase for many people. (Johns Hopkins Medicine)
Why it happens: sensitivity, not a hormone imbalance
One of the most common misconceptions about PMDD is that your body is making "too much" or "too little" of a reproductive hormone. The research points to something more specific and, for many people, more validating: hormone levels can be normal, while the brain's response to normal cyclical hormone shifts is not. PMDD appears to be less about a broken cycle and more about a nervous system that reacts strongly to the cycle's usual rise-and-fall pattern. As one review puts it, "Premenstrual Dysphoric Disorder (PMDD) is a cyclical mood disorder that affects approximately 3%-8% of menstruating individuals and leads to significant impairment in social functioning and quality of life. The disorder is characterized by increased sensitivity to neuroactive steroids (NASs) fluctuations, particularly allopregnanolone (ALLO)" (*Current Neuropharmacology*, 2026).
A key player is allopregnanolone, a metabolite of progesterone. In many bodies, allopregnanolone works like a calming signal because it acts on the brain's GABA system — one of the systems that helps turn down threat, tension, and overarousal. In PMDD, the issue seems to be that this signal does not land normally. The same cyclical progesterone-and-allopregnanolone changes that another person might barely notice can, in a sensitive brain, feel like irritability, dread, panic, rage, depression, insomnia, or a sudden loss of emotional control. Research describes how "NASs imbalance critically impairs GABAergic signaling and HPA axis function, precipitating profound structural and functional abnormalities within critical emotion-regulation circuits, notably the prefrontal-limbic system" (*Current Neuropharmacology*, 2026).
That is why PMDD is not a character flaw, a "bad attitude," or a willpower problem. It is a body-brain timing problem. The systems that regulate stress, threat detection, and emotional braking become more reactive during a predictable part of the cycle. Neuroimaging research fits this picture: "Neuroimaging evidence confirms heightened amygdala reactivity to NASs in PMDD patients" (*Current Neuropharmacology*, 2026). The amygdala is part of the brain's emotional-alarm network, so when it becomes more reactive, ordinary stress can feel louder, sharper, and harder to shut off.
This "sensitivity" model also explains why the luteal phase — the time after ovulation and before your period — can become a vulnerable window. Progesterone rises after ovulation, its neuroactive metabolites shift with it, and then those levels change again before bleeding starts. Research points to "the luteal phase, characterised by changing progesterone levels, as a window of vulnerability to stress-related disorders" (*npj Women's Health*, 2026). In other words, it is not simply the presence of hormones that matters. It is the change in those hormones, filtered through a nervous system that is unusually sensitive to that change.
This is also the logic behind common medical treatment paths. SSRIs are widely supported as first-line medication treatment for PMDD, and they may be used continuously or only during the luteal phase, depending on the person and clinician. For some people, hormonal options — including certain combined oral contraceptives or other approaches that reduce ovulation-driven hormone fluctuation — are considered because they aim to smooth, shorten, or bypass the cycle shifts that trigger symptoms. Any medication choice should be individualized by a clinician; do not start or self-adjust treatment on your own. Detailed options belong on the dedicated [PMDD treatment page](/pmdd/treatment/). (Cleveland Clinic)
The core symptoms
PMDD can show up in your body, your sleep, your appetite, and your energy — but the mood symptoms are the center of the diagnosis. In DSM-5 terms, the pattern is not "I felt awful before one period." It is a repeated cycle pattern: in most cycles, at least five symptoms appear in the final week before bleeding starts, begin to ease within a few days after the period begins, and are minimal or gone in the week after your period. At least one of those symptoms has to be a core mood symptom. (DSM-5 / NCBI Bookshelf)
Core mood symptoms — at least one is required for diagnosis:
Marked irritability, anger, or more conflict with other people
Markedly depressed mood, hopelessness, or harsh self-critical thoughts
Marked anxiety, tension, or feeling keyed up / on edge
Marked mood swings, sudden tearfulness, or feeling unusually sensitive to rejection
These are not "just being emotional." They are signs that your stress, threat, and mood-regulation systems may be reacting differently in the luteal phase — the window after ovulation and before your period. That is why PMDD can feel like a switch flips: your life is the same, but your brain and body suddenly process it with much less room, less safety, and less resilience. Authoritative clinical summaries list the same mood cluster — irritability or anger, depression or despair, anxiety or tension, mood swings, and tearfulness — as the hallmark symptom group. (DSM-5 / NCBI Bookshelf)
Additional symptoms — these count toward the total:
Decreased interest in usual activities
Difficulty concentrating, often felt as "brain fog"
Fatigue, lethargy, or low energy
Appetite changes, overeating, or specific food cravings
Sleeping too much or insomnia
Feeling overwhelmed or out of control
Physical symptoms — breast tenderness or swelling, bloating, joint or muscle aches, headaches, cramps, or a sensation of weight gain
The physical symptoms matter. Breast tenderness, bloating, muscle or joint pain, headaches, sleep changes, and food cravings can all be part of PMDD. But what separates PMDD from ordinary PMS is usually the degree of mood disruption and impairment: you may be able to function normally for much of the month, then suddenly feel unable to work, study, parent, connect, or trust your own thoughts in the days before your period. (Johns Hopkins Medicine)
To meet the DSM-5 threshold, symptoms must cause clinically significant distress or interfere with work, school, usual activities, relationships, or home life. They also need to be tied to the menstrual cycle rather than being a constant baseline mood disorder, thyroid problem, medication effect, substance effect, or another condition that simply gets worse premenstrually. Confirmation is usually done with prospective daily tracking for at least two symptomatic cycles; a clinician can make a provisional diagnosis earlier, but the pattern is what makes the diagnosis stronger. (DSM-5 / NCBI Bookshelf)
⚠️ A safety note that belongs on this page: PMDD is associated with a higher risk of suicidal thoughts and suicidal behavior. If you notice that your darkest thoughts arrive on a monthly schedule, that timing is not random noise — it is important clinical information, and it is treatable. If you are in the U.S. and you might hurt yourself or you feel unable to stay safe, call or text 988 to reach the Suicide & Crisis Lifeline at any time; SAMHSA says trained crisis counselors are available day or night. (*Journal of Women's Health*, 2021; SAMHSA — 988)
How PMDD is diagnosed
There is no single blood test, scan, or hormone panel that can confirm PMDD. That can feel frustrating, because the symptoms are very physical and very real — but the problem usually isn't "abnormal hormones" showing up on a lab report. Research suggests people with PMDD often have normal peripheral ovarian hormone levels, while the nervous system appears unusually sensitive to normal cycle-related hormone shifts. In research settings, diagnosis is anchored to standardized criteria, with participants "diagnosed according to the American Psychiatric Association DSM-5" (*Journal of Magnetic Resonance Imaging*, 2026).
In practice, the reference method is prospective symptom charting across at least two menstrual cycles. That means you track symptoms day by day, not from memory at the end of the month. Clinicians are looking for a pattern: symptoms rise in the luteal phase — the days after ovulation and before bleeding — then improve or clear after your period starts, with a symptom-light stretch after menses. The DRSP — Daily Record of Severity of Problems — is one standardized tool used for this, and ACOG's premenstrual-disorders guideline includes diagnosis as part of its clinical framework for PMS and PMDD care. (ACOG Clinical Practice Guideline No. 7)
Your clinician should also check whether something else is driving or amplifying the symptoms. PMDD can look like depression, anxiety, thyroid problems, perimenopause, chronic fatigue, IBS, or another condition that happens to flare before your period. The timing matters: PMDD is not just "feeling worse sometimes." It is a repeating cycle-linked pattern that disrupts your life, relationships, work, school, or sense of control, then eases at a different point in the cycle. (Johns Hopkins Medicine)
This is also where a lot of people get stuck. PMDD is frequently missed or misattributed. Research documents "barriers to care, including misdiagnosis, missed diagnosis, and limited practitioner knowledge" (*Journal of Health Psychology*, 2026), and many people spend years being told their cyclical symptoms are "just PMS," anxiety, or depression before the pattern is recognized. A prospective log changes the conversation: it turns "I feel like I fall apart every month" into dates, severity scores, cycle phase, impairment, and recovery.
Arriving with a prospective log — ideally two cycles of daily symptom-and-cycle data — is the single most useful thing you can do to shorten that road. Even one cycle can help start the appointment; two cycles gives your clinician the pattern PMDD diagnosis depends on.
Can a wearable or app diagnose PMDD?
No. A wearable or tracking app can't diagnose PMDD, because PMDD is diagnosed clinically: a clinician looks at timing, symptom severity, functional impact, and whether another condition could better explain what's happening; DSM-5 criteria also call for prospective daily ratings across at least two symptomatic cycles. That means the useful question isn't "Can my watch tell me I have PMDD?" It's "Can my data show my provider the pattern clearly enough to take the next step?" (StatPearls / NCBI Bookshelf)
Tracking can help with that. When you log mood, sleep, energy, pain, appetite, overwhelm, conflict, cycle day, and bleeding — not just the worst day — you create a before/during/after map. PMDD is about recurrence: symptoms rise before your period, ease after bleeding starts, and leave a different baseline for the rest of the cycle. A clean two-cycle record can make that rhythm harder to dismiss and easier to discuss in an appointment. (StatPearls / NCBI Bookshelf)
A wearable adds another layer, but it still doesn't replace diagnosis. HRV can change across the menstrual cycle, and research has found lower vagally mediated HRV in the luteal phase compared with the follicular phase in naturally cycling participants. In plain language: the same body may show a different autonomic "weather pattern" after ovulation, when progesterone is higher and many people with PMDD enter their vulnerable window. (*Psychoneuroendocrinology* / PMC)
That's the Welltory difference: context, not a label. Cycle-phase HRV patterns can help you see the luteal window in your own data, connect it with your symptom log, and bring your provider a concrete, repeatable picture instead of trying to reconstruct the last two months from memory. Welltory tracks and records these patterns for you; it does not diagnose PMDD or any condition.
When to see a doctor
See a clinician if your premenstrual symptoms are severe, cyclical, and interfering with your life — not just annoying, but strong enough to disrupt work, school, relationships, parenting, sleep, or your ability to feel like yourself. PMDD symptoms typically appear in the week or two before your period and improve within a few days after bleeding starts; that "on/off" pattern matters because it helps separate PMDD from depression, anxiety, thyroid problems, or other conditions that can look similar but need different care. (Johns Hopkins Medicine)
Pay special attention if mood symptoms dominate: irritability that feels hard to control, depression, anxiety, sudden mood swings, feeling overwhelmed, or losing interest in your usual life. These symptoms are not a character flaw or "just PMS." PMDD is a recognized health condition that can be treated, and many clinicians will ask you to track symptoms across cycles so the timing is clear before choosing the right treatment plan. (Johns Hopkins Medicine)
If you have thoughts of self-harm or suicide at any point in the cycle, get help right away — call or text 988 in the U.S., contact emergency services, or go to the nearest emergency department if you might act on those thoughts. You do not need to wait until your period starts to see whether it passes. Safety comes first. (National Institute of Mental Health)
How we made it
Made with AI tools, then edited, fact-checked, and medically reviewed by the Welltory team.
Trust block — authors and reviewers
Data analysis by Jane Smorodnikova — the founder and CEO of Welltory. A recognized tech leader with two Master's degrees and experience at MIT, she has scaled Welltory to over 17 million users.
Written by Kseniia Iaroslavtseva — COO at Welltory. She reviews scientific research and turns it into structured, readable insights.
Reviewed by Anna Elitzur — Medical Advisor & Mental Health Expert. Anna holds her medical degree and reviews health content across topics for medical accuracy and consistency with current clinical guidelines and research.
Related reading
[PMDD overview](/pmdd/general/)
[PMDD symptoms](/pmdd/symptoms/)
[PMDD treatment](/pmdd/treatment/)
Related topics: [HRV](/hrv/), [Anxiety](/anxiety/)
Discounts for blog readers: up to 36% off
See what affects your energy, stress, sleep, and daily state with Welltory
This article is for educational purposes only and does not replace medical diagnosis or treatment. PMDD is a diagnosable condition — if the pattern sounds like you, talk to a qualified clinician. If you are having thoughts of harming yourself, in the US you can call or text 988 (Suicide & Crisis Lifeline) any time, or contact your local emergency services.
Was this helpful?
Ask AI for a summary of page
Written by Jane Smorodnikova
The founder and CEO of Welltory. A recognized tech leader with two Master's degrees and experience at MIT, she has scaled Welltory to over 17 million users.
Written by Kseniia Iaroslavtseva
She reviews scientific research and turns it into structured, readable insights.
Reviewed by Anna Elitzur
-2.jpg)
With her medical degree, Anna reviews Welltory's health content for medical accuracy and alignment with current clinical guidelines and research.
References
- Yang Q, Wang X, Shi P, et al. Neuroactive Steroid Regulation in Premenstrual Dysphoric Disorder: Cross-Integration of Metabolism, Dysfunction, Neurobiology, and Precision Medicine. Current Neuropharmacology (2026). PMID 41863265; DOI 10.2174/011570159X413940251127061938 — prevalence commonly cited as 3–8%, ALLO/neuroactive-steroid sensitivity, GABA/HPA/prefrontal-limbic mechanisms, amygdala reactivity, SSRI–ALLO modulation.
- Mosalisa M, Roomaney R. Medical gas-lighting, diagnostic odyssey and self-advocacy among women with premenstrual dysphoric disorder from nine countries. Journal of Health Psychology (2026). DOI 10.1177/13591053251401286 — PMDD as a cyclical condition, late-luteal timing, diagnostic barriers, misdiagnosis, missed diagnosis, practitioner-knowledge gaps.
- Increased Glymphatic System Activity and Hypothalamic Connectivity in Patients With Premenstrual Dysphoric Disorder. Depression and Anxiety (2026). PMCID PMC13080338 — luteal-phase symptom characterization, DSM-5/DRSP-based prospective screening, neuroimaging findings in PMDD.
- Menstrual cycle variations in stress vulnerability and sociability relate to mental health symptoms and libido. npj Women's Health (2026). PMCID PMC13090119 — mid-to-late luteal phase as a window of vulnerability for stress-related symptoms and premenstrual mental-health symptoms.
- Exploring White Matter Microstructural Abnormalities Using MRI in Women With PMDD. Journal of Magnetic Resonance Imaging (2026). DOI 10.1002/jmri.70318 — case-control DTI study; participants diagnosed according to DSM-5.
- American Psychiatric Association / NCBI Bookshelf. DSM-IV to DSM-5 Premenstrual Dysphoric Disorder Comparison — exact DSM-5 timing language: symptoms in the final week before menses, improvement within a few days after menses starts, minimal/absent symptoms postmenses.
- Mishra S, Elliott H, Marwaha R. Premenstrual Dysphoric Disorder. StatPearls / NCBI Bookshelf — DSM-5 clinical criteria summary: ≥5 symptoms, ≥1 core mood symptom, impairment, exclusion of other disorders, confirmation with prospective daily ratings across at least two symptomatic cycles.
- ACOG. Management of Premenstrual Disorders: ACOG Clinical Practice Guideline No. 7. Obstetrics & Gynecology (2023). PMID 37973069; DOI 10.1097/AOG.0000000000005426 — guideline framework for PMS/PMDD diagnosis, background, and management.
- Freeman EW. Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis. Psychoneuroendocrinology (2003). PMID 12892988; DOI 10.1016/S0306-4530(03)00099-4 — diagnostic definitions, differential diagnosis, and prospective daily diaries as diagnostic standard; no hormone/lab test for diagnosis.
- Epperson CN, Steiner M, Hartlage SA, et al. Premenstrual Dysphoric Disorder: Evidence for a New Category for DSM-5. American Journal of Psychiatry / PMC — evidence base for DSM-5 PMDD category and prospective symptom ratings.
- Hantsoo L, Epperson CN. Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle. Neurobiology of Stress (2020). PMID 32435664; PMCID PMC7231988; DOI 10.1016/j.ynstr.2020.100213 — ALLO-GABA-A sensitivity model, stress sensitivity, and SSRI/GABA-targeted treatment rationale.
- Timby E, Bäckström T, Nyberg S, et al. Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls — a pilot study. Psychopharmacology (2016). PMID 26960697 — commonly cited 3–8% prevalence range and altered ALLO sensitivity in PMDD.
- Eisenlohr-Moul TA, et al. Premenstrual Disorders: A Primer and Research Agenda for Psychologists. Clinical Psychology: Science and Practice / PMC — PMDD vs PME distinction, luteal-phase confinement, symptom remission after menses, and two months of daily DSM-5 symptom ratings.
- Lin J, Nunez C, Susser L, Gershengoren L. Understanding premenstrual exacerbation: navigating the intersection of the menstrual cycle and psychiatric illnesses. Frontiers in Psychiatry (2024). PMID 39176230; PMCID PMC11338788; DOI 10.3389/fpsyt.2024.1410813 — PME definition and distinction from PMDD.
- Eisenlohr-Moul TA, Schmalenberger KM, Owens SA, et al. A DSM-5-based tool to monitor concurrent mood and premenstrual symptoms: the McMaster Premenstrual and Mood Symptom Scale (MAC-PMSS). BMC Women's Health / PMC — prospective daily charting, high false-positive risk with retrospective assessment, and clinical need for two-month tracking.
- Johns Hopkins Medicine. Premenstrual Dysphoric Disorder (PMDD). — patient-facing definition, timing, symptom list, differential diagnosis, and treatment overview.
- Cleveland Clinic. Premenstrual Dysphoric Disorder (PMDD): Causes & Treatment. — patient-facing symptom coverage, diagnosis basics, SSRIs, drospirenone/ethinyl estradiol birth-control option, and rule-out of other conditions.
- Office on Women's Health. Premenstrual dysphoric disorder (PMDD) and Premenstrual syndrome (PMS). — patient-facing PMS/PMDD distinction, symptom lists, timing, FDA-approved SSRI and drospirenone/ethinyl estradiol notes.
- Prasad D, Wollenhaupt-Aguiar B, Kidd KN, et al. Suicidal Risk in Women with Premenstrual Syndrome and Premenstrual Dysphoric Disorder: A Systematic Review and Meta-Analysis. Journal of Women's Health (2021). PMID 34415776 — increased suicidal ideation and attempt risk in PMDD/PMS and recommendation for suicide-risk assessment.
- SAMHSA. 988 Suicide & Crisis Lifeline / 988 Key Messages. — U.S. call/text/chat 988 access, trained crisis counselors, 24/7 support.
- Schmalenberger KM, Tauseef HA, Barone JC, et al. Menstrual Cycle Changes in Vagally-Mediated Heart Rate Variability Are Associated with Progesterone: Evidence from Two Within-Person Studies. Psychoneuroendocrinology / PMC — lower vagally mediated HRV in the luteal phase vs follicular phase and progesterone-HRV association.
